HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $15 to $35.
HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $15 to $35.